Albendazole is effective treatment for chronic strongyloidiasis.
A total of 301 British ex-Far East prisoners of war, many of whom worked on the Thai-Burma Railway during World War II, consecutively attended The Liverpool School of Tropical Medicine for clinical review between January 1987 and August 1990. Fifty-two (17%) were found to have chronic strongyloidiasis. Diagnostic criteria included any of the following: characteristic larva currens rash, positive Strongyloides serology, and positive stool examination. Forty-seven were evaluable 6 months, after therapy with albendazole 400 mg twice daily for 3 days, which resulted in a 75% cure rate. Cure was defined as disappearance of the rash, if present, negative serology and negative stool examination. Patients who had more than one positive diagnostic feature were only considered cured if both or all had disappeared or become negative. All 12 of the patients in whom initial treatment failed were given a second course of albendazole: three further cures were obtained in eight evaluable patients. The overall cure rate was 81%. The only side-effects recorded were mild nausea and diarrhoea in one patient. We suggest that albendazole should be the treatment of choice for chronic strongyloidiasis.
Archibald
L K
LK
Liverpool School of Tropical Medicine.
Beeching
N J
NJ
Gill
G V
GV
Bailey
J W
JW
Bell
D R
DR
D000368:Aged; D015766:Albendazole / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003967:Diarrhea / Q000139:chemically induced; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces / Q000469:parasitology; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced; D013322:Strongyloidiasis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D015766:Albendazole